“Gas station heroin” crisis spreads as states ban tianeptine; Connecticut latest to outlaw risky, unapproved drug
Tianeptine, an unapproved tricyclic antidepressant sold at gas stations and online, is producing opioid‑like effects, serious overdoses and dependence. Several states have moved to ban this risky, falsely marketed “gas station heroin” to protect public health.
Key takeaways
- Unapproved and widely available: Products labeled as supplements containing tianeptine are sold at convenience stores, vape shops and online, despite not being FDA‑approved. FDA, Mayo Clinic
- Opioid‑like harms: At higher doses tianeptine stimulates mu‑opioid receptors, producing euphoria, dependence and life‑threatening respiratory depression. NCBI, FDA
- Regulatory response: At least 14 states have restricted or banned tianeptine; Connecticut recently added it to Schedule I amid rising poison‑control and overdose reports. VCU Health, House Energy & Commerce
- Public action advised: Officials urge removal from shelves, immediate emergency care for suspected overdoses and use of naloxone by trained responders. SAMHSA, FDA
What is tianeptine and why is it sold at gas stations?
Tianeptine was developed and used as an antidepressant in some other countries, but it is not approved by the U.S. Food and Drug Administration for any use in the United States. Versions of the drug are marketed here as pills, powders, salts and liquids and often labeled as dietary supplements, “brain boosters” or remedies for pain and anxiety. That marketing and easy availability have created a false sense of safety for consumers. FDA, Mayo Clinic
How tianeptine acts in the body
At low doses, tianeptine can alter serotonin signaling and produce modest mood effects. With increasing doses — particularly in recreational use — the drug stimulates mu‑opioid receptors, the same targets activated by heroin and many prescription opioids. This opioid activity can cause intense euphoria, a high risk of dependence, and, in overdose, severe respiratory depression and death. Medical literature and clinical summaries document this dose‑dependent shift from antidepressant to opioid effects. VCU Health, NCBI, FDA
Health dangers documented by authorities
Reports to poison control centers, case studies and agency alerts describe a spectrum of harms: severe sedation, coma, respiratory depression, arrhythmias, seizures, gastrointestinal symptoms and death. Withdrawal syndromes resembling opioid withdrawal — sweating, diarrhea and intense cravings — have been reported. The Drug Enforcement Administration and the FDA have issued safety advisories; state health alerts, including a New Jersey notice, document regional outbreaks. New Jersey Health Alert (PDF), VCU Health
Real‑world incidents
Public health investigations have linked tianeptine products to clusters of severe illness. In 2024, a New Jersey cluster involved a product labeled “Neptune’s Fix” that contained tianeptine together with synthetic cannabinoids; that outbreak produced deaths, prolonged heart rhythm problems and seizures. Poison control centers nationwide have logged sharp increases in exposures since 2016, with notable spikes in 2024. FDA, New Jersey Health Alert (PDF)
Why public health officials and clinicians are alarmed
“With increasing doses, the mu‑opioid receptor stimulation may become lethal,” said Robert Schwaner, M.D., vice chair of system clinical affairs at Stony Brook Emergency Medicine, comparing tianeptine’s mechanism to heroin and other opioids where heavy mu‑opioid stimulation can lead to respiratory arrest.
Clinicians warn the unpredictable shift from serotonin effects to potent opioid activity means even people seeking mood relief may face unexpected, life‑threatening respiratory depression.
State and federal actions so far
Regulatory responses have proceeded state‑by‑state. At least 14 states have placed tianeptine on controlled substance schedules or banned its sale. Connecticut recently added tianeptine to Schedule I, joining other emerging substances such as kratom derivatives and nitazenes. Connecticut leaders cited deceptive marketing, candy‑like flavors and risk to youth and people with substance‑use disorders as drivers for the change. The FDA issued a public safety alert, urged retailers to remove products, and prompted a nationwide recall of certain Neptune Resources products in 2024. VCU Health, House Energy & Commerce
Marketing tactics that increase risk
Investigators note that flavorings, candy‑style packaging and false therapeutic claims drive experimentation and misuse. Sellers often claim these products treat pain, anxiety, depression or even opioid withdrawal — claims not supported by FDA approval in the U.S. Such tactics mask potent opioid effects and help create a market for what some call “Tianeptine gas station heroin.” FDA, Mayo Clinic, Talbot Health
What regulators and clinicians recommend
Consumers: Do not buy or use products labeled as tianeptine sold as supplements. If someone is unresponsive after using such a product, call emergency services immediately — opioid‑like respiratory depression can be fatal.
Clinicians and responders: Be prepared to treat severe sedation and respiratory depression; naloxone may be effective for tianeptine overdose but treatment must be managed by medical professionals. FDA, VCU Health
Help and resources
People seeking help for tianeptine or other substance use problems can call SAMHSA’s National Helpline for free, confidential support 24/7 in English and Spanish. The helpline can connect callers to local treatment services.
Implications for the Inland Empire, California
- Public health and hospitals: Emergency departments may see tianeptine overdoses; clinicians should treat presentations similar to opioid overdose and be ready to use naloxone. VCU Health, FDA
- Law enforcement and regulation: Local agencies should monitor retail sales at convenience stores, vape shops and online sellers shipping to the region and consider ordinances mirroring other states’ bans. House Energy & Commerce
- Communities and schools: Candy‑like flavors and small packaging can attract teens; schools and parent groups should educate about risks and emphasize these are unapproved drugs. Mayo Clinic, FDA
- Harm reduction and treatment access: Ensure naloxone availability, prepare to treat opioid‑like withdrawal and link residents to SAMHSA resources. SAMHSA
- Consumer vigilance: Avoid buying unregulated mood enhancers or pain remedies from gas stations and online; report suspicious products to state health departments and the FDA’s MedWatch program. FDA
Reporting and transparency
This investigation draws on public health alerts, government notices, clinical reports and state actions. Key sources include the U.S. Food and Drug Administration, state health alerts and clinical summaries from academic medical centers. Full source list follows.
Sources
- FDA — New gas‑station heroin (tianeptine) product trend
- Mayo Clinic — Tianeptine: Is safe use possible?
- VCU Health — What you need to know about gas‑station heroin
- NCBI — Research summaries on tianeptine
- New Jersey Health Alert (PDF)
- House Energy & Commerce — Press materials
- Talbot Health — Emerging substances
- SAMHSA — National Helpline
Reporting by Times Media Service.
